12/17/2013
Kerry Mohrien, PharmD, BCPS; Timothy H. Self, PharmD; Carrie S. Oliphant, PharmD, BCPS
This review will highlight clinically significant drug interactions amongst the NOACs—dabigatran, rivaroxaban, and apixaban—to provide strategies for managing these interactions.
